Sign in

NCT07273409Recruiting

Pancreatic Neuroendocrine Tumour - Optimal Surgical Debulking or Not

PANcreatic Neuroendocrine Tumour - Optimal Surgical Debulking Or Not (PANTODON). A Prospective, Two Armed, Parallel, Randomised, Controlled International Multicentre Study on WHO Grade 1-2, Stage 4 Pancreatic NET

Source: ClinicalTrials.gov · Last updated 22 Jan 2026

Brief summary (registry, in English)

Pancreatic neuroendocrine tumours (pan-NETs) are neoplasms arising from the endocrine cells of the pancreas. Although pan-NET are quite rare, the incidence is on the rise and together with other abdominal neuroendocrine tumours an approximate incidence in Sweden would be 850 patients per year extrapolating from Norwegian data. Pan-NET are divided into symptomatic hormone producing tumours (such as insulinomas/glucagonomas/VIPomas) or non-functioning tumours that often are asymptomatic. As early symptoms often are lacking in non-functioning-pan-NET, many patients present with distant metastases and are thus beyond a curative surgical approach at the time of diagnosis. Metastatic non-functioning pan-NETs present a significant challenge and the optimal management remains a subject of debate. This is a prospective, two armed, parallel, randomised, controlled, international multi-centre study, aiming to investigate if a near-total tumour debulking (intervention) in metastatic (stage 4) GI-WHO grade 1-2 pan- NET, with or without oncologic treatment, is superior to oncologic treatment alone (control), with regards to overall survival, health-related quality of life, participant performance status, time until hospitalisation, adverse event characteristics and cost in the short and long term.

Status (registry)
Recruiting
Study type
Interventional
Enrollment
200 (estimated)
First submitted
24 Sept 2025
Start date
9 Jan 2026
Primary completion date
31 May 2033
Lead sponsor
Uppsala University
NCT number
NCT07273409

What you commit to

  • Study type: Interventional
  • Planned participants: 200
  • From 9 Jan 2026 to the primary completion date, 31 May 2033
  • 4 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Risk of surgery deemed too high by MDT or Surgeon (reason to be specified)
  • Previous surgery for pan-NET.
  • Hormonal symptoms caused by a functional pan-NET, not controllable by medical therapy, indicating debulking surgery.
  • Previously included in the current study.

Other illness

  • The study subject does not fit into either STRATA: a) STRATUM 1: Less than 70% of the total tumour volume can be debulked, b) STRATUM 2: no FDG-PET avid disease is observed OR all (100%) FDG-PET avid tumour is not resectable.

Age

  • Subject not fit for surgery due to comorbidity or advanced age (reason to be specified)

Other

  • Pregnancy
  • Other reason in the opinion of the Principal Investigator (reason to be specified).

Who the study is looking for

  • Pan- NET, ENETS/AJCC stage 4 determined by CT or PET/CT
  • Primary tumour or metastases confirmed as Pancreatic NET GI-WHO grade 1-2 pan-NET by histology or cytology
  • Age ≥ 18 years
  • Written informed consent obtained

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (4)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
Sahlgrenska University Hospital
Coordinator of this site? Confirm its status
GothenburgSwedenRecruiting
Skåne University Hospital
Coordinator of this site? Confirm its status
LundSwedenNot yet recruiting
Karolinska University Hospital
Coordinator of this site? Confirm its status
StockholmSwedenRecruiting
Uppsala University Hospital
Coordinator of this site? Confirm its status
UppsalaSwedenRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.